BACKGROUND: Most studies of leukocyte telomere length (LTL) focus on diagnosed disease in one system. A more encompassing depiction of health is disease burden, defined here as the sum of noninvasively measured markers of structure or function in different organ systems. We determined if (a) shorter LTL is associated with greater age-related disease burden and (b) shorter LTL is less strongly associated with disease in individual systems or diagnosed chronic conditions (cardiovascular disease, stroke, pulmonary disease, diabetes, kidney disease, arthritis, or depression). METHODS: LTL was measured by Southern blots of terminal restriction fragment length. Age-related disease was measured noninvasively and included carotid intima-media thickness, lung vital capacity, white matter grade, cystatin-C, and fasting glucose; each graded 0 (best tertile), 1 (middle tertile), or 2 (worst tertile) and summed (0 to 10) to estimate disease burden. Of 419 participants randomly selected for LTL measurement, 236 had disease burden assessed (mean [SD] age 74.2 [4.9] years, 42.4% male, 86.8% white, and 13.2% black). RESULTS: Mean (SD) LTL was 6,312 (615) bp, and disease score was 4.7 (2.1) points. An SD higher disease score (β [SE] = -132 [47] bp, p < .01), age (β [SE] = -107 [46], p = .02) or carotid thickness (β [SE] = -95 [40] bp, p = .02) was associated with shorter LTL, but diagnosed conditions or number of conditions were not associated with LTL. Disease score attenuated the effect of age on LTL by 35%. CONCLUSION: LTL was associated with a characterization of age-related disease burden across multiple physiologic systems, which was comparable to, but independent of, its association with age.
BACKGROUND: Most studies of leukocyte telomere length (LTL) focus on diagnosed disease in one system. A more encompassing depiction of health is disease burden, defined here as the sum of noninvasively measured markers of structure or function in different organ systems. We determined if (a) shorter LTL is associated with greater age-related disease burden and (b) shorter LTL is less strongly associated with disease in individual systems or diagnosed chronic conditions (cardiovascular disease, stroke, pulmonary disease, diabetes, kidney disease, arthritis, or depression). METHODS: LTL was measured by Southern blots of terminal restriction fragment length. Age-related disease was measured noninvasively and included carotid intima-media thickness, lung vital capacity, white matter grade, cystatin-C, and fasting glucose; each graded 0 (best tertile), 1 (middle tertile), or 2 (worst tertile) and summed (0 to 10) to estimate disease burden. Of 419 participants randomly selected for LTL measurement, 236 had disease burden assessed (mean [SD] age 74.2 [4.9] years, 42.4% male, 86.8% white, and 13.2% black). RESULTS: Mean (SD) LTL was 6,312 (615) bp, and disease score was 4.7 (2.1) points. An SD higher disease score (β [SE] = -132 [47] bp, p < .01), age (β [SE] = -107 [46], p = .02) or carotid thickness (β [SE] = -95 [40] bp, p = .02) was associated with shorter LTL, but diagnosed conditions or number of conditions were not associated with LTL. Disease score attenuated the effect of age on LTL by 35%. CONCLUSION: LTL was associated with a characterization of age-related disease burden across multiple physiologic systems, which was comparable to, but independent of, its association with age.
Authors: Charles Matthews; Isabelle Gorenne; Stephen Scott; Nicola Figg; Peter Kirkpatrick; Andrew Ritchie; Martin Goddard; Martin Bennett Journal: Circ Res Date: 2006-06-22 Impact factor: 17.367
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: S Demissie; D Levy; E J Benjamin; L A Cupples; J P Gardner; A Herbert; M Kimura; M G Larson; J B Meigs; J F Keaney; A Aviv Journal: Aging Cell Date: 2006-08 Impact factor: 9.304
Authors: Linda F Fried; Ronit Katz; Mark J Sarnak; Michael G Shlipak; Paulo H M Chaves; Nancy Swords Jenny; Catherine Stehman-Breen; Dan Gillen; Anthony J Bleyer; Calvin Hirsch; David Siscovick; Anne B Newman Journal: J Am Soc Nephrol Date: 2005-10-26 Impact factor: 10.121
Authors: W T Longstreth; T A Manolio; A Arnold; G L Burke; N Bryan; C A Jungreis; P L Enright; D O'Leary; L Fried Journal: Stroke Date: 1996-08 Impact factor: 7.914
Authors: Michael G Shlipak; Linda F Fried; Mary Cushman; Teri A Manolio; Do Peterson; Catherine Stehman-Breen; Anthony Bleyer; Anne Newman; David Siscovick; Bruce Psaty Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: Kristin Litzelman; Whitney P Witt; Ronald E Gangnon; F Javier Nieto; Corinne D Engelman; Marsha R Mailick; Halcyon G Skinner Journal: Am J Epidemiol Date: 2014-04-29 Impact factor: 4.897
Authors: Jason L Sanders; Alice M Arnold; Robert M Boudreau; Calvin H Hirsch; Jorge R Kizer; Robert C Kaplan; Anne R Cappola; Mary Cushman; Mini E Jacob; Stephen B Kritchevsky; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Kevin S King; Julia Kozlitina; Roger N Rosenberg; Ronald M Peshock; Roderick W McColl; Christine K Garcia Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Nisha Bansal; Mary A Whooley; Mathilda Regan; Charles E McCulloch; Joachim H Ix; Elissa Epel; Elizabeth Blackburn; Jue Lin; Chi-Yuan Hsu Journal: Am J Nephrol Date: 2012-10-25 Impact factor: 3.754
Authors: Jason L Sanders; Ryan L Minster; M Michael Barmada; Amy M Matteini; Robert M Boudreau; Kaare Christensen; Richard Mayeux; Ingrid B Borecki; Qunyuan Zhang; Thomas Perls; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2013-08-02 Impact factor: 6.053